{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T22:23:47Z","timestamp":1790807027880,"version":"4.1.0"},"reference-count":36,"publisher":"American Diabetes Association","issue":"3","license":[{"start":{"date-parts":[[2017,2,21]],"date-time":"2017-02-21T00:00:00Z","timestamp":1487635200000},"content-version":"vor","delay-in-days":55,"URL":"http:\/\/www.diabetesjournals.org\/content\/license"}],"content-domain":{"domain":["diabetesjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2017,3,1]]},"abstract":"<jats:sec>\n                  <jats:title>OBJECTIVE<\/jats:title>\n                  <jats:p>We aimed to investigate the role of serum levels of various apolipoproteins on the risk for type 2 diabetes (T2D).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>RESEARCH DESIGN AND METHODS<\/jats:title>\n                  <jats:p>We used data from 971 individuals from the prospective population-based Rotterdam Study. We studied the association of HDL cholesterol (HDL-C), apoA1, apoCIII, apoD, and apoE as well as the ratios of apolipoproteins with apoA1 with the risk of T2D. All apolipoproteins, ratios, and HDL-C levels were naturally log-transformed to reach normal distribution. First, their cross-sectional associations with fasting glucose and insulin were investigated by using linear regression. Second, Cox proportional hazard models were used to examine whether apolipoproteins predict the risk for T2D among individuals free of diabetes at baseline. We also studied the apolipoproteins jointly by calculating the apolipoproteinic score from the first step and then performing Cox regression with it.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>RESULTS<\/jats:title>\n                  <jats:p>During a median follow-up of 13.5 years, diabetes developed in 110 individuals. After adjustment for age, sex, BMI, parental history of diabetes, hypertension, alcohol use, smoking, prevalent cardiovascular disease, and serum lipid\u2013reducing agents, HDL-C (per 1 SD naturally log-transformed hazard ratio 0.74 [95% CI 0.57, 0.97], apoCIII (1.65 [1.42, 1.91]), apoE (1.36 [1.18, 1.55]), apoCIII-to-apoA1 ratio (1.72 [1.51, 1.95]), apoE-to-apoA1 ratio (1.28 [1.13, 1.45]), and apolipoproteinic score (1.60 [1.39, 1.83]) remained significant. Only apoCIII (1.42 [1.03, 1.96]) and apoCIII-to-apoA1 ratio (1.56 [1.04, 2.36]) survived the adjustment for triglycerides in the last model.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>CONCLUSIONS<\/jats:title>\n                  <jats:p>Serum apoCIII levels as well as apoCIII-to-apoA1 ratio are associated with incident T2D. They are associated independent of known risk factors and stronger than HDL-C levels.<\/jats:p>\n               <\/jats:sec>","DOI":"10.2337\/dc16-1295","type":"journal-article","created":{"date-parts":[[2016,12,29]],"date-time":"2016-12-29T02:10:38Z","timestamp":1482977438000},"page":"346-351","update-policy":"https:\/\/doi.org\/10.2337\/ada-journal-policies","source":"Crossref","is-referenced-by-count":44,"title":["Serum Levels of Apolipoproteins and Incident Type 2 Diabetes: A Prospective Cohort Study"],"prefix":"10.2337","volume":"40","author":[{"given":"Adela","family":"Brahimaj","sequence":"first","affiliation":[{"name":"Department of Epidemiology, Erasmus University Medical Center, Rotterdam, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Symen","family":"Ligthart","sequence":"additional","affiliation":[{"name":"Department of Epidemiology, Erasmus University Medical Center, Rotterdam, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. Arfan","family":"Ikram","sequence":"additional","affiliation":[{"name":"Department of Epidemiology, Erasmus University Medical Center, Rotterdam, the Netherlands"},{"name":"Department of Neurology, Erasmus University Medical Center, Rotterdam, the Netherlands"},{"name":"Department of Radiology, Erasmus University Medical Center, Rotterdam, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Albert","family":"Hofman","sequence":"additional","affiliation":[{"name":"Department of Epidemiology, Erasmus University Medical Center, Rotterdam, the Netherlands"},{"name":"Harvard School of Public Health, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oscar H.","family":"Franco","sequence":"additional","affiliation":[{"name":"Department of Epidemiology, Erasmus University Medical Center, Rotterdam, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric J.G.","family":"Sijbrands","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Erasmus University Medical Center, Rotterdam, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maryam","family":"Kavousi","sequence":"additional","affiliation":[{"name":"Department of Epidemiology, Erasmus University Medical Center, Rotterdam, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abbas","family":"Dehghan","sequence":"additional","affiliation":[{"name":"Department of Epidemiology, Erasmus University Medical Center, Rotterdam, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1167","published-online":{"date-parts":[[2016,12,28]]},"reference":[{"key":"2022031301483495000_B1","doi-asserted-by":"crossref","first-page":"2893","DOI":"10.1001\/jama.1990.03440210043030","article-title":"Cardiovascular risk factors in confirmed prediabetic individuals. Does the clock for coronary heart disease start ticking before the onset of clinical diabetes","volume":"263","author":"Haffner","year":"1990","journal-title":"JAMA"},{"key":"2022031301483495000_B2","doi-asserted-by":"crossref","first-page":"2104","DOI":"10.1161\/ATVBAHA.111.241463","article-title":"Selective hepatic insulin resistance, VLDL overproduction, and hypertriglyceridemia","volume":"32","author":"Sparks","year":"2012","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"2022031301483495000_B3","doi-asserted-by":"crossref","first-page":"628","DOI":"10.2337\/dc14-0645","article-title":"Lipoprotein particles and incident type 2 diabetes in the multi-ethnic study of atherosclerosis","volume":"38","author":"Mackey","year":"2015","journal-title":"Diabetes Care"},{"key":"2022031301483495000_B4","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1089\/met.2014.0050","article-title":"Lipoprotein insulin resistance index: a lipoprotein particle-derived measure of insulin resistance","volume":"12","author":"Shalaurova","year":"2014","journal-title":"Metab Syndr Relat Disord"},{"key":"2022031301483495000_B5","doi-asserted-by":"crossref","DOI":"10.2337\/db14-1603","article-title":"HDL cholesterol and risk of type 2 diabetes: a Mendelian randomization study","author":"Haase","year":"2015","journal-title":"Diabetes"},{"key":"2022031301483495000_B6","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.ijcard.2008.12.066","article-title":"The paradox of high apolipoprotein A-I levels independently predicting incident type-2 diabetes among Turks","volume":"142","author":"Onat","year":"2010","journal-title":"Int J Cardiol"},{"key":"2022031301483495000_B7","doi-asserted-by":"crossref","first-page":"474","DOI":"10.2337\/dc10-0793","article-title":"Serum apolipoprotein AI and B are stronger biomarkers of diabetic retinopathy than traditional lipids","volume":"34","author":"Sasongko","year":"2011","journal-title":"Diabetes Care"},{"key":"2022031301483495000_B8","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1186\/1472-6823-13-42","article-title":"The association between the apolipoprotein A1\/high density lipoprotein-cholesterol and diabetes in Taiwan - a cross-sectional study","volume":"13","author":"Jian","year":"2013","journal-title":"BMC Endocr Disord"},{"key":"2022031301483495000_B9","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1016\/j.atherosclerosis.2015.03.034","article-title":"Associations of multiple lipoprotein and apolipoprotein measures with worsening of glycemia and incident type 2 diabetes in 6607 non-diabetic Finnish men","volume":"240","author":"Fizelova","year":"2015","journal-title":"Atherosclerosis"},{"key":"2022031301483495000_B10","doi-asserted-by":"crossref","first-page":"E1352","DOI":"10.1210\/jc.2013-1680","article-title":"Role of HDL cholesterol and estimates of HDL particle composition in future development of type 2 diabetes in the general population: the PREVEND study","volume":"98","author":"Abbasi","year":"2013","journal-title":"J Clin Endocrinol Metab"},{"key":"2022031301483495000_B11","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1007\/s00125-011-2092-x","article-title":"Association of an APOC3 promoter variant with type 2 diabetes risk and need for insulin treatment in lean persons","volume":"54","author":"van Hoek","year":"2011","journal-title":"Diabetologia"},{"key":"2022031301483495000_B12","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1111\/j.1464-5491.2009.02814.x","article-title":"Serum apolipoprotein C-III in high-density lipoprotein: a key diabetogenic risk factor in Turks","volume":"26","author":"Onat","year":"2009","journal-title":"Diabet Med"},{"key":"2022031301483495000_B13","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1007\/s10654-015-0082-x","article-title":"The Rotterdam Study: 2016 objectives and design update","volume":"30","author":"Hofman","year":"2015","journal-title":"Eur J Epidemiol"},{"key":"2022031301483495000_B14","first-page":"1","volume-title":"Definition and Diagnosis of Diabetes Mellitus and Intermediate Hyperglycemia: Report of a WHO\/IDF Consultation","author":"World Health Organization","year":"2006"},{"key":"2022031301483495000_B15","doi-asserted-by":"crossref","first-page":"5239","DOI":"10.1021\/pr100520x","article-title":"Proteomic characterization of human plasma high density lipoprotein fractionated by gel filtration chromatography","volume":"9","author":"Gordon","year":"2010","journal-title":"J Proteome Res"},{"key":"2022031301483495000_B16","doi-asserted-by":"crossref","first-page":"3631","DOI":"10.1073\/pnas.71.9.3631","article-title":"The primary structure of high density apolipoprotein-glutamine-I","volume":"71","author":"Baker","year":"1974","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2022031301483495000_B17","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1021\/bi00879a033","article-title":"Studies of the composition and structure of serum lipoproteins: isolation, purification, and characterization of very low density lipoproteins of human serum","volume":"4","author":"Gustafson","year":"1965","journal-title":"Biochemistry"},{"key":"2022031301483495000_B18","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/0021-9150(86)90036-5","article-title":"Gemfibrozil increases both apo A-I and apo E concentrations. Comparison to other lipid regulators in cholesterol-fed rats","volume":"59","author":"Krause","year":"1986","journal-title":"Atherosclerosis"},{"key":"2022031301483495000_B19","doi-asserted-by":"crossref","first-page":"3101","DOI":"10.1210\/jcem.85.9.6773","article-title":"Risk for diabetes mellitus in middle-aged Caucasian male participants of the PROCAM study: implications for the definition of impaired fasting glucose by the American Diabetes Association. Prospective Cardiovascular M\u00fcnster","volume":"85","author":"von Eckardstein","year":"2000","journal-title":"J Clin Endocrinol Metab"},{"key":"2022031301483495000_B20","doi-asserted-by":"crossref","first-page":"834","DOI":"10.2337\/diabetes.55.03.06.db05-1380","article-title":"Susceptibility to type 1 diabetes is associated with ApoCIII gene haplotypes","volume":"55","author":"Hokanson","year":"2006","journal-title":"Diabetes"},{"key":"2022031301483495000_B21","doi-asserted-by":"crossref","first-page":"E2611","DOI":"10.1073\/pnas.1423849112","article-title":"Apolipoprotein CIII links islet insulin resistance to \u03b2-cell failure in diabetes","volume":"112","author":"\u00c5vall","year":"2015","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2022031301483495000_B22","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/j.ecl.2006.06.002","article-title":"Diabetic dyslipidemia","volume":"35","author":"Chahil","year":"2006","journal-title":"Endocrinol Metab Clin North Am"},{"key":"2022031301483495000_B23","doi-asserted-by":"crossref","first-page":"1722","DOI":"10.1161\/CIRCULATIONAHA.109.875807","article-title":"Apolipoprotein C-III and the metabolic basis for hypertriglyceridemia and the dense low-density lipoprotein phenotype","volume":"121","author":"Zheng","year":"2010","journal-title":"Circulation"},{"key":"2022031301483495000_B24","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1172\/JCI111711","article-title":"Modulation of lipoprotein lipase activity by apolipoproteins. Effect of apolipoprotein C-III","volume":"75","author":"Wang","year":"1985","journal-title":"J Clin Invest"},{"key":"2022031301483495000_B25","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1194\/jlr.M900346-JLR200","article-title":"Expression of apolipoprotein C-III in McA-RH7777 cells enhances VLDL assembly and secretion under lipid-rich conditions","volume":"51","author":"Sundaram","year":"2010","journal-title":"J Lipid Res"},{"key":"2022031301483495000_B26","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1056\/NEJMoa1400283","article-title":"Antisense inhibition of apolipoprotein C-III in patients with hypertriglyceridemia","volume":"373","author":"Gaudet","year":"2015","journal-title":"N Engl J Med"},{"key":"2022031301483495000_B27","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.1001\/jama.2009.1619","article-title":"Major lipids, apolipoproteins, and risk of vascular disease","volume":"302","author":"Di Angelantonio","year":"2009","journal-title":"JAMA"},{"key":"2022031301483495000_B28","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1056\/NEJMoa070635","article-title":"Effect of torcetrapib on the progression of coronary atherosclerosis [published correction appears in N Engl J Med 2007;357:835]","volume":"356","author":"Nissen","year":"2007","journal-title":"N Engl J Med"},{"key":"2022031301483495000_B29","doi-asserted-by":"crossref","first-page":"2109","DOI":"10.1056\/NEJMoa0706628","article-title":"Effects of torcetrapib in patients at high risk for coronary events","volume":"357","author":"Barter","year":"2007","journal-title":"N Engl J Med"},{"key":"2022031301483495000_B30","doi-asserted-by":"crossref","first-page":"1886","DOI":"10.1161\/01.CIR.102.16.1886","article-title":"VLDL, apolipoproteins B, CIII, and E, and risk of recurrent coronary events in the Cholesterol and Recurrent Events (CARE) trial","volume":"102","author":"Sacks","year":"2000","journal-title":"Circulation"},{"key":"2022031301483495000_B31","doi-asserted-by":"crossref","first-page":"410","DOI":"10.2174\/157016112800812755","article-title":"Proteomics investigations of HDL: challenges and promise","volume":"10","author":"Vaisar","year":"2012","journal-title":"Curr Vasc Pharmacol"},{"key":"2022031301483495000_B32","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1007\/s11892-008-0010-5","article-title":"Why is HDL functionally deficient in type 2 diabetes","volume":"8","author":"Kontush","year":"2008","journal-title":"Curr Diab Rep"},{"key":"2022031301483495000_B33","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1111\/j.1472-8206.2009.00739.x","article-title":"Lipid modification in type 2 diabetes: the role of LDL and HDL","volume":"23","author":"Verg\u00e8s","year":"2009","journal-title":"Fundam Clin Pharmacol"},{"key":"2022031301483495000_B34","doi-asserted-by":"crossref","first-page":"169","DOI":"10.3803\/EnM.2013.28.3.169","article-title":"High density lipoprotein: a therapeutic target in type 2 diabetes","volume":"28","author":"Barter","year":"2013","journal-title":"Endocrinol Metab (Seoul)"},{"key":"2022031301483495000_B35","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1097\/MOL.0b013e3283412279","article-title":"Possible contributions of lipoproteins and cholesterol to the pathogenesis of diabetes mellitus type 2","volume":"22","author":"von Eckardstein","year":"2011","journal-title":"Curr Opin Lipidol"},{"key":"2022031301483495000_B36","first-page":"923","article-title":"Reference values for apolipoprotein A-I and apolipoprotein B in serum still depend on choice of assay techniques","volume":"32","author":"Boerma","year":"1994","journal-title":"Eur J Clin Chem Clin Biochem"}],"container-title":["Diabetes Care"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/diabetesjournals.org\/care\/article-pdf\/40\/3\/346\/548227\/dc161295.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/diabetesjournals.org\/care\/article-pdf\/40\/3\/346\/548227\/dc161295.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,13]],"date-time":"2022-03-13T05:49:38Z","timestamp":1647150578000},"score":1,"resource":{"primary":{"URL":"https:\/\/diabetesjournals.org\/care\/article\/40\/3\/346\/36895\/Serum-Levels-of-Apolipoproteins-and-Incident-Type"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,12,28]]},"references-count":36,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2016,12,28]]},"published-print":{"date-parts":[[2017,3,1]]}},"URL":"https:\/\/doi.org\/10.2337\/dc16-1295","relation":{},"ISSN":["0149-5992","1935-5548"],"issn-type":[{"value":"0149-5992","type":"print"},{"value":"1935-5548","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,12,28]]}}}